Edwards Lifesciences Corporation (EW)

Market Cap	41.01B
Revenue (ttm)	6.31B
Net Income (ttm)	4.16B
Shares Out	589.80M
EPS (ttm)	6.89
PE Ratio	10.10
Forward PE	29.38
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,776,532
Open	70.55
Previous Close	70.20
Day's Range	68.47 - 70.61
52-Week Range	58.93 - 96.12
Beta	1.12
Analysts	Buy
Price Target	76.60 (+10.15%)
Earnings Date	Oct 24, 2024

About EW

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical struct...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Mar 27, 2000
• Employees: 19,800
• Stock Exchange: NYSE
• Ticker Symbol: EW
• Website: https://www.edwards.com

Financial Performance

In 2023, Edwards Lifesciences's revenue was $6.00 billion, an increase of 11.56% compared to the previous year's $5.38 billion. Earnings were $1.40 billion, a decrease of -7.85%.

Analyst Forecast

According to 21 analysts, the average rating for EW stock is "Buy." The 12-month stock price forecast is $76.6, which is an increase of 10.15% from the latest price.

Price Target

$76.6

(10.15% upside)

Analyst Consensus: Buy